Benjamin Saylor

Articles

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

February 24th 2025

Darolutamide generated lower treatment discontinuation rates and longer MFS vs enzalutamide or apalutamide in both Black and White patients with nmCRPC.

Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age

February 23rd 2025

Darolutamide plus ADT and docetaxel demonstrated efficacy benefits in men with mHSPC regardless of whether they were younger or older than 75 years of age.

Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status

February 15th 2025

Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

June 6th 2024

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Neoadjuvant Darolutamide/ADT Followed By Radical Prostatectomy Is Safe/Effective in Localized Prostate Cancer

January 25th 2024

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Boosts rPFS in Taxane-Naïve mCRPC After Prior AR Inhibitor

October 23rd 2023

Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor.

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

October 21st 2023

Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy.

Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial Carcinoma

June 5th 2023

The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC

June 3rd 2023

Patients with nonmetastatic castration-resistant prostate cancer who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide.

Hypertension Linked With Worse Outcomes for Patients With Upper Tract Urothelial Cancer Undergoing Nephroureterectomy

April 30th 2023

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

April 28th 2023

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab Produces High DFS Rates in BCG-unresponsive NMIBC

February 18th 2023

Pembrolizumab monotherapy led notable antitumor activity with manageable toxicity in patients with Bacillus Calmette-Guérin–unresponsive, papillary high-risk non–muscle-invasive bladder cancer

Darolutamide Demonstrates Long-term Safety in nmCRPC

February 16th 2023

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies

November 19th 2022

Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.

Technological Advances Specify Optimal Therapies in Prostate Cancer

November 16th 2022

Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment landscape.

Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer

September 12th 2022

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

Perioperative Nivolumab Fails to Improve RFS Vs Surgery Alone in RCC

September 10th 2022

Perioperative nivolumab did not improve recurrence-free survival compared with surgery alone in patients with renal cell carcinoma.

Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Does Not Affect Cabazitaxel Systemic Exposure in mCRPC

June 7th 2022

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel

June 5th 2022

177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities